© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Bausch + Lomb Corporation (BLCO) stock surged +0.12%, trading at $17.15 on NYSE, up from the previous close of $17.13. The stock opened at $17.25, fluctuating between $16.93 and $17.25 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | 17.16 | 17.30 | 16.94 | 17.15 | 398.03K |
| Aug 27, 2026 | 17.28 | 17.39 | 16.95 | 17.13 | 558.71K |
| Aug 26, 2026 | 17.33 | 17.35 | 17.05 | 17.25 | 349.9K |
| Aug 25, 2026 | 17.44 | 17.44 | 17.00 | 17.25 | 476.33K |
| Aug 24, 2026 | 17.29 | 17.56 | 17.21 | 17.32 | 290.49K |
| Aug 21, 2026 | 17.29 | 17.45 | 17.16 | 17.24 | 233.05K |
| Aug 20, 2026 | 17.33 | 17.47 | 17.04 | 17.20 | 403.7K |
| Aug 19, 2026 | 17.26 | 17.77 | 17.26 | 17.45 | 537.93K |
| Aug 18, 2026 | 17.06 | 17.49 | 17.04 | 17.04 | 407.8K |
| Aug 17, 2026 | 17.00 | 17.12 | 16.77 | 17.00 | 407.65K |
| Aug 14, 2026 | 17.04 | 17.17 | 16.91 | 17.05 | 226.52K |
| Aug 13, 2026 | 16.72 | 17.04 | 16.60 | 16.98 | 395.34K |
| Aug 12, 2026 | 16.63 | 16.89 | 16.28 | 16.76 | 387.57K |
| Aug 11, 2026 | 16.70 | 17.05 | 16.70 | 16.87 | 195.85K |
| Aug 10, 2026 | 16.67 | 17.00 | 16.60 | 16.83 | 324.09K |
| Aug 07, 2026 | 16.43 | 16.78 | 16.36 | 16.78 | 257.67K |
| Aug 06, 2026 | 16.81 | 16.81 | 16.31 | 16.35 | 328.65K |
| Aug 05, 2026 | 16.84 | 16.84 | 16.15 | 16.76 | 221.06K |
| Aug 04, 2026 | 16.78 | 16.78 | 16.50 | 16.68 | 310.98K |
| Aug 03, 2026 | 16.99 | 17.11 | 16.55 | 16.77 | 429.06K |
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.
| Employees | 13000 |
| Beta | 0.55 |
| Sales or Revenue | $4.15B |
| 5Y Sales Change% | 0.13% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Instruments & Supplies |